The Chief of Myeloma at Roswell Park Comprehensive Cancer Center will deliver the latest findings of the CARTITUDE-2 clinical trial at the 2024 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), running Feb. 21-24 in San Antonio, Texas.

Roswell Park Comprehensive Cancer Center congratulates Director of Pharmaceutical Chemistry Ravindra Pandey, PhD, for being named a National Academy of Inventors (NAI) Fellow.

Up to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene mutation, which is associated with a high risk of relapse and a very poor prognosis. But clinical studies have shown that drugs called FLT3 inhibitors can extend long-term survival in these patients, especially when given in combination with other treatments. A phase 2 clinical trial led by Roswell Park Comprehensive Cancer Center tested that strategy for treating FLT3-mutated AML, and the encouraging results are newly reported in Journal of Clinical Oncology, a journal of the American Society of Clinical Oncology.

Roswell Park Comprehensive Cancer Center is spotlighting our 2024 Super Bowl MVPs — the Most Valuable Pups who are considered the “goodest boys and girls” by patients and staff alike. The cancer center will debut “Tails of Hope,” a local television commercial featuring its therapy dog program, airing in the Buffalo market during the big game on Sunday, February 11.

A research study led by a multidisciplinary team of scientists at Roswell Park Comprehensive Cancer Center details evidence on the therapeutic efficacy of a compound that targets a key genetic feature of pancreatic cancer. The work, newly published in Cancer Research, a journal of the American Association for Cancer Research, illustrates potential clinical applications for the novel anticancer agent MRTX1133 and outlines its effect on both the tumor and the surrounding environment.